Sonnet BioTherapeutics Holdings
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Sonnet BioTherapeutics Holdings generated cash of -$8,607,723, which is more than the previous year. Cash used in financing activities reached the amount of $6,494,920 last year. Net change in cash is therefore -$2,124,803.
Cash Flow
| 2015 | -5.36M | -10.49M | 17.13M |
|---|---|---|---|
| 2016 | -509.15K | -430.81K | -21.98K |
| 2017 | -724.43K | -439.30K | 1.35M |
| 2018 | -1.10M | -1.25M | 1.31M |
| 2019 | -2.22M | -2.44M | 2.25M |
| 2020 | -15.61M | -76.18K | 23.00M |
| 2021 | -22.55M | -3.62K | 42.82M |
| 2022 | -27.68M | -896.47K | 4.01M |
| 2023 | -21.34M | -443.25K | 21.00M |
| 2024 | -8.60M | -12K | 6.49M |
SONN Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 2.27M | 3.05M | 27.62M | 7.34M | 35.65K | 5.41K | 438.49K | 268.57K | 1.23M | 245.82K |
Operating activities | ||||||||||
Net income | -7.43M | -18.83M | -29.72M | -24.98M | -24.26M | -4.87M | -6.86M | -6.79M | -4.27M | -14.45M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 83.11K | 75.75K | 93.25K | 95.16K | 58.31K | 2.16M | 1.81M | 2.28M | 2.34M | 2.36M |
Stock-based compensation expense | 231.19K | 248.62K | 876.36K | 1.37M | 370.05K | 430K | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 231.19K | 248.62K | 876.36K | 1.37M | 370.05K | 430K | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 91.79K | 114.00K | 35.15K | -336.54K | -758.09K |
Inventories | 0 | 0 | 0 | 0 | 0 | 8.88K | 72.80K | 23.06K | 33.21K | -130.60K |
Accounts payable | 48.42K | -2.63M | 971.04K | 1.72M | 168.80K | 1.38M | 2.51M | 1.03M | 1.54M | 1.16M |
Cash generated by operating activities | -8.60M | -21.34M | -27.68M | -22.55M | -15.61M | -2.22M | -1.10M | -724.43K | -509.15K | -5.36M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | -896.47K | -3.62K | -76.18K | -2.39M | -1.69M | -1.62M | -1.19M | -1.79M |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 1.43M | 770K | 1.18M | 751.45K | -9.02M |
Cash generated by investing activities | -12K | -443.25K | -896.47K | -3.62K | -76.18K | -2.44M | -1.25M | -439.30K | -430.81K | -10.49M |
Financing activities | ||||||||||
Common Stock Issued | 3.89M | 21.00M | 1.84M | 42.84M | 19.07M | 2.78M | 1.68M | 1.28M | 257.17K | 14.92M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -748 | 0 | -20.43K | -110.73K | 0 | -270.57K | 68.65K | -279.15K | 1.86M |
Cash used in financing activities | 6.49M | 21.00M | 4.01M | 42.82M | 23.00M | 2.25M | 1.31M | 1.35M | -21.98K | 17.13M |
Net Change In Cash | -2.12M | -778.62K | -24.56M | 20.27M | 7.31M | 30.23K | 85.61K | 169.91K | -961.95K | 1.28M |
Cash at end of period | 149.45K | 2.27M | 3.05M | 27.62M | 7.34M | 35.65K | 524.11K | 438.49K | 268.57K | 1.52M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |